Meloxicam in Mohs Micrographic Surgery
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-110
SponsorUniversity of Oklahoma
About this trial
The goal of this clinical trial is to explore alternative methods of postoperative pain control in Mohs micrographic surgery. The main aims are:
* To provide more information to the Mohs surgery community regarding postoperative pain control. * Reducing pain improves the overall comfort and well-being of patients, leading to a better post-operative experience. * To provide patients with an alternative and potentially superior NSAID for pain control (compared to standard-of-care ibuprofen).
Researchers will compare 1) a single of dose Meloxicam 7.5 mg, followed by acetaminophen 500 mg; 2) a single dose of Meloxicam 15 mg, followed by acetaminophen 500 mg; 3) a single dose of acetaminophen 500 mg, followed by alternating ibuprofen 200 mg and acetaminophen 500 mg to see which better moderate pain control and patient satisfaction.
Participants will be asked to complete pain and patient satisfaction surveys.
Eligibility criteria
Qualifiers
All adult patients who consents to the study and are undergoing Mohs micrographic surgery at the University of Oklahoma.
Disqualifiers
Women who are pregnant, suspected to be pregnant, or planning to become pregnant during the study period will be excluded from participation.
Chronic liver disease (chronic hepatitis, acute hepatitis, cirrhosis, NASH, NAFLD, alcoholic liver disease, hemochromatosis, Wilson's disease)
Chronic kidney disease stage III or greater,
Aspirin-sensitive asthma
Trial design
Treatments tested in this trial
- Meloxicam 7.5 mg
- Meloxicam 15 mg
- Acetaminophen 500mg
Treatment groups
300 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov